Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novavax Inc (NQ: NVAX )

3.950 -0.200 (-4.82%)
Streaming Delayed Price Updated: 12:34 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novavax Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
50 51 Next >
AMC Entertainment Is Most Expensive Stock For Short Sellers, But What Other Stocks Top The List?
With its persistent net losses, a recent reverse stock split, massive shareholder dilution and nearly $5 billion in debt, AMC Entertainment Holdings Inc (NYSE: AMC) may seem like an obvious candidate... 
Via Benzinga
7 Short-Squeeze Stocks That Are Driving Hedge Funds Crazy
Although market bears seem to have the right idea with these short-squeeze stocks, the bulls continue to frustrate them. 
Via InvestorPlace
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. 
Via InvestorPlace
Stop! Don’t Infect Your Portfolio With Toxic Novavax Stock.
Novavax used those two dreaded words - "going concern" - and that's a signal for sensible investors to stay away from NVAX stock. 
Via InvestorPlace
FTX's Native Token Might Be Relaunched, Putin Personally Approved Arrest Of American Journalist Evan Gershkovich, Fox News-Dominion Voting Systems Trial To Start Monday: Today's Top Stories
Benzinga 
Via Benzinga
Why Novavax Stock Slipped on Thursday
The biotech makes it official: One of its leaders is stepping down. 
Via The Motley Fool
Novavax Plans to Cut $50 Million in Costs, COVID-19 Vaccine Remains Only Marketed Product
Novavax Inc's (NASDAQ: NVAX) CEO, newly appointed CEO John Jacobs, said the company would cut about $50 million in costs in Q1 of 2023 and plans further cuts. 
Via Benzinga
Novavax Outlook: Why NVAX Stock Could 12X in the Next 12 Months
Recent, positive clinical data released by Novavax (NVAX) indicates that NVAX stock could surge almost 12 times in the next year. 
Via InvestorPlace
March CPI 2023: The Numbers That All Investors Are Watching Today
The March CPI data is out and there are a few key numbers that investors will want to keep in mind while trading on Wednesday. 
Via InvestorPlace
Why Is Novavax (NVAX) Stock Moving Today?
Novavax (NVAX) stock is on the move Wednesday despite a lack of news from the vaccine company and no heavy trading volume. 
Via InvestorPlace
Why Novavax Stock Is Seeing Blue Skies
Novavax Inc (NASDAQ: NVAX) shares are trading higher by 9.88% to $8.34 Thursday afternoon. The stock may be reacting to the company's presentations at the 2023 World Vaccine Congress this week. 
Via Benzinga
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Monday, 3/31, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
1 Green Flag and 1 Red Flag for Novavax
Novavax shares have dropped more than 90% over the past year. 
Via The Motley Fool
This Growth Stock Is Down 90%. Is It Time to Sell or Buy?
Think twice about picking up shares of Novavax, even if you're brave. 
Via The Motley Fool
1 Stock to Buy and 1 to Avoid Before the Next Bull Market
These stocks could move in opposite directions come the next bull market. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 ‘Fallen Angel’ Stocks to Sell Before They Plummet Again
These seven stocks to sell have already become out of favor among investors, but that doesn't mean they can't sink further from here. 
Via InvestorPlace
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many... 
Via Benzinga
1 Growth Stock With 741% Upside, According to Wall Street
The vaccine maker has delivered returns of this size before, but things have changed a lot since. 
Via The Motley Fool
1 Stock You Need to Sell Before the Next Bull Market
Freeing up your capital now is preferable to losing more of it on this stock. 
Via The Motley Fool
Short Squeeze Stocks: BBBY, SI and 3 Other Stocks Ready to Squeeze
Short squeeze stocks are all over Wall Street in the wake of the regional banking crisis. Which names should you keep an eye out for? 
Via InvestorPlace
3 Stocks That Won’t Survive a Major Market Crash
These three stocks appear to be particularly exposed to a potential market crash, and should be on investors' sell lists right now. 
Via InvestorPlace
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats 
Via News Direct
Topics Death Economy
Exposures COVID-19 Death Economy
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
With the COVID pandemic still ongoing, having claimed  more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and... 
Via Benzinga
2 Growth Stocks That Are Trading at a Huge Discount Right Now -- Maybe Rightfully So
Focus on the prospects for their business, not their valuations. 
Via The Motley Fool
3 Vaccine Stocks to Watch for Their Post-Pandemic Moves
The vaccine stocks Pfizer, Moderna, and Novavax all have approved Covid-19 vaccines. They'll soon need new sources of revenue. 
Via InvestorPlace
Novavax Stock: Bear vs. Bull
The stock has brought investors eye-popping gains and losses over the past few years. 
Via The Motley Fool
Novavax Just Dropped a Bombshell on Investors: Even Management Is Questioning Its Future
Can Novavax survive the year? 
Via The Motley Fool
FDA's Regulatory Delay is The Reason For Novavax, Lucira Health's Failure: WSJ Report
Failures of Covid vaccine maker Novavax Inc (NASDAQ: NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ: LHDX) show that companies often succeed or fail, owing to the whims of the government.&nb 
Via Benzinga
US Stocks Could Consolidate As S&P 500, Nasdaq Futures Tick Up Ahead Of Fed Chair Powell's Congressional Testimony
Stocks could pause on Monday after returning to winning ways in the past week, as the focus shifts to Fed Chair Jerome Powell’s two-day Congressional testimony this week. Cues From Last Week’s... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
50 51 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.